Publication Date
| In 2024 | 0 |
| Since 2023 | 0 |
| Since 2020 (last 5 years) | 0 |
| Since 2015 (last 10 years) | 1 |
| Since 2005 (last 20 years) | 1 |
Descriptor
| Asperger Syndrome | 1 |
| Autism | 1 |
| Children | 1 |
| Drug Therapy | 1 |
| Intervention | 1 |
| Outcomes of Treatment | 1 |
| Pervasive Developmental… | 1 |
| Randomized Controlled Trials | 1 |
| Safety | 1 |
Source
| Autism: The International… | 1 |
Author
| Ali, Sanjida | 1 |
| Aman, Michael G. | 1 |
| Andersen, Kristen A. | 1 |
| Graham, Stephen M. | 1 |
| Hardan, Antonio Y. | 1 |
| Hendren, Robert L. | 1 |
| Jia, X Daniel | 1 |
| Lateiner, Jordan E. | 1 |
| Luchini, Rachel | 1 |
| Mallick, Madhuja | 1 |
| Melmed, Raun D. | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Social Responsiveness Scale | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkHardan, Antonio Y.; Hendren, Robert L.; Aman, Michael G.; Robb, Adelaide; Melmed, Raun D.; Andersen, Kristen A.; Luchini, Rachel; Rahman, Rezwanur; Ali, Sanjida; Jia, X Daniel; Mallick, Madhuja; Lateiner, Jordan E.; Palmer, Robert H.; Graham, Stephen M. – Autism: The International Journal of Research and Practice, 2019
Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder. MEM-MD-91, a 50-week open-label trial, identified memantine extended-release treatment responders for enrollment into MEM-MD-68, a 12-week randomized, double-blind,…
Descriptors: Children, Autism, Pervasive Developmental Disorders, Drug Therapy
